Lucentis receive DME approval in EU

(Ophtalmology Times Europe)
Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its therapy Lucentis for the treatment of patients with diabetic macular oedema (DME).
Full Story ->

Leave a Reply

Your email address will not be published. Required fields are marked *